Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 24
1.
Int J Antimicrob Agents ; 62(2): 106895, 2023 Aug.
Article En | MEDLINE | ID: mdl-37339710

OBJECTIVES: Although approximately 40 years have passed since Japanese spotted fever (JSF) was first reported in Japan, its treatment has not yet been standardised. As in other rickettsial infections, tetracycline (TC) is the first-line treatment, but successful instances of fluoroquinolone (FQ) combination therapy in severe cases have been reported. However, the effectiveness of TC plus FQ combined treatment (TC+FQ) remains controversial. Therefore, the antipyretic effect of TC+FQ was evaluated in this study. METHODS: A comprehensive search of published JSF case reports was conducted to extract individual patient data. In cases where it was possible to extract temperature data, after homogenising patient characteristics, time-dependent changes in fever type from the date of the first visit was evaluated for the TC and TC+FQ groups. RESULTS: The primary search yielded 182 cases, with individual data evaluations resulting in a final analysis of 102 cases (84 in the TC group and 18 in the TC+FQ group) that included temperature data. The TC+FQ group had significantly lower body temperature compared with the TC group from Days 3 to 4. CONCLUSIONS: Although TC monotherapy for JSF can eventually result in defervescence, the duration of fever is longer compared with other rickettsial infections such as scrub typhus. The results suggest that the antipyretic effect of TC+FQ was more effective, with a potential shortening of the duration that patients suffer from febrile symptoms.


Anti-Bacterial Agents , Spotted Fever Group Rickettsiosis , Humans , Anti-Bacterial Agents/therapeutic use , Antipyretics , East Asian People , Fever/drug therapy , Fluoroquinolones/therapeutic use , Spotted Fever Group Rickettsiosis/diagnosis , Spotted Fever Group Rickettsiosis/drug therapy , Tetracycline/therapeutic use
2.
Biochem Biophys Res Commun ; 663: 96-103, 2023 06 30.
Article En | MEDLINE | ID: mdl-37121130

The tick-borne bacterium Rickettsia parkeri is an obligate intracellular pathogen that belongs to spotted fever group rickettsia (SFGR). The SFG pathogens are characterized by their ability to infect and rapidly proliferate inside host vascular endothelial cells that eventually result in impairment of vascular endothelium barrier functions. Benidipine, a wide range dihydropyridine calcium channel blocker, is used to prevent and treat cardiovascular diseases. In this study, we tested whether benidipine has protective effects against rickettsia-induced microvascular endothelial cell barrier dysfunction in vitro. We utilized an in vitro vascular model consisting of transformed human brain microvascular endothelial cells (tHBMECs) and continuously monitored transendothelial electric resistance (TEER) across the cell monolayer. We found that during the late stages of infection when we observed TEER decrease and when there was a gradual increase of the cytoplasmic [Ca2+], benidipine prevented these rickettsia-induced effects. In contrast, nifedipine, another cardiovascular dihydropyridine channel blocker specific for L-type Ca2+ channels, did not prevent R. parkeri-induced drop of TEER. Additionally, neither drug was bactericidal. These data suggest that growth of R. parkeri inside endothelial cells is associated with impairment of endothelial cell monolayer integrity due to Ca2+ flooding through specific, benidipine-sensitive T- or N/Q-type Ca2+ channels but not through nifedipine-sensitive L-type Ca2+ channels. Further study will be required to discern the exact nature of the Ca2+ channels and Ca2+ transporting system(s) involved, any contributions of the pathogen toward this process, as well as the suitability of benidipine and new dihydropyridine derivatives as complimentary therapeutic drugs against Rickettsia-induced vascular failure.


Dihydropyridines , Rickettsia , Spotted Fever Group Rickettsiosis , Vascular Diseases , Humans , Calcium Channel Blockers/pharmacology , Calcium Channel Blockers/therapeutic use , Endothelial Cells , Nifedipine/pharmacology , Dihydropyridines/pharmacology , Spotted Fever Group Rickettsiosis/drug therapy
4.
Vet Clin North Am Small Anim Pract ; 52(6): 1305-1317, 2022 Nov.
Article En | MEDLINE | ID: mdl-36336422

Spotted fever rickettsioses are important causes of emerging infectious disease in the United States and elsewhere. Rocky Mountain Spotted Fever, caused by R. rickettsii causes a febrile, acute illness in dogs. Because it circulates in peripheral blood in low copy number and because of the acute nature of the disease, dogs may test PCR and seronegative at the time of presentation. Therefore, therapy with doxycycline must be initiated and continued based on the clinician's index of suspicion. Combining PCR with serologic testing, repeat testing of the same pre-antimicrobial blood sample, and testing convalescent samples for seroconversion facilitates diagnosis. The prognosis can be excellent if appropriate antimicrobial therapy is begun in a timely fashion. It is well established that dogs are sentinels for infection in people in households and communities. Whether R. rickettsii causes illness in cats is not well established. The role of other spotted fever group rickettsia in causing illness in dogs and cats is being elucidated. Veterinarians should keep in mind that novel and well characterized species of SFG Rickettsia are important causes of emerging infectious disease. Veterinarians can play an important role in detecting, defining, and preventing illness in their canine patients and their human companions.


Cat Diseases , Communicable Diseases, Emerging , Dog Diseases , Rickettsia Infections , Rickettsia , Rocky Mountain Spotted Fever , Spotted Fever Group Rickettsiosis , Humans , Dogs , Animals , United States/epidemiology , Cats , Communicable Diseases, Emerging/veterinary , Cat Diseases/diagnosis , Cat Diseases/drug therapy , Dog Diseases/diagnosis , Dog Diseases/drug therapy , Dog Diseases/epidemiology , Rickettsia Infections/diagnosis , Rickettsia Infections/drug therapy , Rickettsia Infections/epidemiology , Rickettsia Infections/veterinary , Rocky Mountain Spotted Fever/diagnosis , Rocky Mountain Spotted Fever/drug therapy , Rocky Mountain Spotted Fever/epidemiology , Rocky Mountain Spotted Fever/veterinary , Spotted Fever Group Rickettsiosis/diagnosis , Spotted Fever Group Rickettsiosis/drug therapy , Spotted Fever Group Rickettsiosis/epidemiology , Spotted Fever Group Rickettsiosis/veterinary , Anti-Bacterial Agents/therapeutic use
6.
J Infect Chemother ; 28(2): 211-216, 2022 Feb.
Article En | MEDLINE | ID: mdl-34711506

INTRODUCTION: Although the mortality rates associated with Japanese spotted fever (JSF) are unknown, advances in testing technology have led to an increase in JSF-induced mortality reported in clinical practice. Up-to-date clinical information is essential for accurate diagnosis and prompt treatment of JSF. METHODS: This retrospective descriptive study included patients with JSF who were treated at the Ise Red Cross Hospital between 2006 and 2019. Diagnostic criteria included positive results of molecular-based tests during the acute phase and/or increased serum-specific antibody titers. This study was performed based on the clinical findings, clinical course, treatment, and prognosis in confirmed cases of JSF. RESULTS: We investigated 239 patients with a confirmed diagnosis of JSF (48.1% men, mean age 69.2 years). Notably, 237 patients received tetracycline antibiotics, and eight patients died (one patient was misdiagnosed and died without adequate treatment). Four of the remaining patients had a multi-organ failure at the time of admission. However, among the 155 consecutive patients who received effective antibiotic therapy after 2012, we observed two deaths; one patient died of hemorrhage secondary to non-steroidal anti-inflammatory drug-induced duodenal ulcer. CONCLUSIONS: Our study showed a case fatality rate of 3.3%, which indicates that JSF is a severe illness. Although a few cases of the fulminant disease are reported, early initiation of therapy was shown to improve JSF-induced mortality by approximately 1%. Prompt initiation of antibiotic therapy (even in the absence of genetic test results) is warranted in cases of suspected JSF.


Red Cross , Spotted Fever Group Rickettsiosis , Aged , Anti-Bacterial Agents/therapeutic use , Female , Hospitals , Humans , Male , Retrospective Studies , Spotted Fever Group Rickettsiosis/diagnosis , Spotted Fever Group Rickettsiosis/drug therapy , Spotted Fever Group Rickettsiosis/epidemiology
7.
Wilderness Environ Med ; 32(4): 499-502, 2021 Dec.
Article En | MEDLINE | ID: mdl-34334302

Tea plantations in Sri Lanka cover the central hills of the island, where spotted fever group (SFG) rickettsial infection is common. In most cases, the history of tick bite is obscure and eschars are not present. A 45-y-old female experienced massive tick bites while working in her tea plantation. She developed fever 2 d after exposure, but the diagnosis of SFG infection was not considered until a skin rash appeared on the eighth day. She had a very high titer of antirickettsial antibodies detected by immunofluorescence assay and responded to doxycycline. Here, we highlight the high risk of exposure to ticks and tick bites within tea estates and its causal relationship to SFG infection, which is increasing in Sri Lanka. Active case detection, notification, surveillance, and community awareness are imperative. Possible preventative measures for tick bites have to be introduced. There is a need to explore the effectiveness of local remedies currently in use.


Rickettsia Infections , Spotted Fever Group Rickettsiosis , Tick Bites , Female , Humans , Spotted Fever Group Rickettsiosis/diagnosis , Spotted Fever Group Rickettsiosis/drug therapy , Spotted Fever Group Rickettsiosis/etiology , Sri Lanka , Tea , Tick Bites/complications
8.
Trop Doct ; 50(4): 330-334, 2020 Oct.
Article En | MEDLINE | ID: mdl-32998655

Acute infectious purpura fulminans is a serious, potentially fatal condition. We present a case series of 11 patients from March 2005 to March 2017, whose clinical symptoms were fever (100%), confusion (63.6%) and headache (55%), and whose common laboratory abnormalities were thrombocytopenia (100%), elevated alkaline phosphatase (70%) and anaemia (63.6%). Three patients (27%) developed gangrene and two presented in shock. Only one grew Neisseria meningitidis in cerebrospinal fluid (CSF) culture and another confirmed by latex agglutination and polymerase chain reaction in CSF. Five others had serology confirmed spotted fever rickettsioses (SFG). All received broad spectrum antibiotics; in 9/11 patients, this included doxycycline or azithromycin. The mean hospital stay was 10.2 days and overall mortality was 18.2%.


Purpura Fulminans/diagnosis , Purpura Fulminans/therapy , Adult , Anti-Bacterial Agents/therapeutic use , Bacteria/drug effects , Bacteria/isolation & purification , Female , Hospitalization , Humans , India , Male , Middle Aged , Purpura Fulminans/mortality , Purpura Fulminans/pathology , Spotted Fever Group Rickettsiosis/diagnosis , Spotted Fever Group Rickettsiosis/drug therapy , Spotted Fever Group Rickettsiosis/mortality , Spotted Fever Group Rickettsiosis/pathology , Treatment Outcome
11.
Medicine (Baltimore) ; 98(46): e17977, 2019 Nov.
Article En | MEDLINE | ID: mdl-31725662

RATIONALE: Both Borrelia burgdorferi sensu lato and spotted fever group Rickettsiae (SFGR) are pathogens carried by ticks. There is a possibility of co-infection with these tick-borne diseases. PATIENT CONCERNS: Male patient, 63 years-of-age, admitted to hospital with skin rash presenting for 1 week and fever with cough and expectoration for 3 days before admission. DIAGNOSES: We diagnosed that the patient was co-infected by B burgdorferi sl and SFGR using laboratory test results and the patient's clinical manifestations. INTERVENTIONS: The patient started therapy with oral minocycline, then levofloxacin by intravenous injection for SFGR. Meanwhile, he was treated with penicillin G sodium, cefoperazone sulbactam sodium and ceftriaxone by intravenous injection for B burgdorferi sl. OUTCOMES: After the patient was in stable condition, he was discharged from hospital. LESSONS: This case report highlights the possibility of co-infection by 2 tick-borne diseases in Urumqi, Xinjiang Uygur Autonomous Region, China. The antibiotic therapy should be based on the detection of pathogenic bacteria, and the different susceptibilities of co-infecting bacteria should be considered.


Lyme Disease/complications , Spotted Fever Group Rickettsiosis/complications , Tick-Borne Diseases/complications , Anti-Bacterial Agents/therapeutic use , Borrelia burgdorferi , China , Humans , Lyme Disease/drug therapy , Male , Middle Aged , Polymerase Chain Reaction , Spotted Fever Group Rickettsiosis/drug therapy , Tick-Borne Diseases/drug therapy
12.
J Infect Chemother ; 25(11): 917-919, 2019 Nov.
Article En | MEDLINE | ID: mdl-31186196

The study was conducted to determine the minimum inhibitory concentrations (MICs) of several antibacterial agents against Rickettsia japonica, which causes Japanese spotted fever. A plaque reduction assay as an in vitro culture method was conducted to determine the MICs of antibacterial agents (4 types of tetracyclines: tetracycline, doxycycline, minocycline, and tigecycline; 3 types of quinolones: ciprofloxacin, ofloxacin, and levofloxacin; and 2 types of macrolides: azithromycin and clarythromycin) against R. japonica. R. japonica was sensitive to the antibacterial agents tested with MICs similar to those against other spotted fever rickettsia determined in previously described plaque reduction assays.


Anti-Bacterial Agents/therapeutic use , Rickettsia Infections/drug therapy , Rickettsia/drug effects , Humans , Microbial Sensitivity Tests/methods , Rickettsia Infections/microbiology , Spotted Fever Group Rickettsiosis/drug therapy , Spotted Fever Group Rickettsiosis/microbiology
13.
Rheumatol Int ; 39(9): 1643-1650, 2019 Sep.
Article En | MEDLINE | ID: mdl-31134290

Rickettsia rickettsii, a tick borne disease, is the pathogen responsible for inducing Rocky Mountain Spotted Fever (RMSF), an illness that can progress to fulminant multiorgan failure and death. We present a case where R. rickettsii, acquired on a camping trip, precipitated a flare of peripheral arthritis and episcleritis in an HLA-B27 positive patient. Although Yersinia, Salmonella, Mycobacteria, Chlamydia, Shigella, Campylobacter, and Brucella have been previously associated with HLA-B27 spondyloarthritis, this unusual case demonstrates that obligate intracellular rickettsial organisms, and specifically, R. rickettsii, can also induce flares of HLA-B27 spondyloarthritis. Rickettsial infections in general can rapidly become fatal in both healthy and immunosuppressed patients, and thus, prompt diagnosis and therapy are required.


Certolizumab Pegol/administration & dosage , HLA-B27 Antigen/immunology , Immunocompromised Host , Rickettsia rickettsii/immunology , Spondylarthritis/drug therapy , Spotted Fever Group Rickettsiosis/microbiology , Tumor Necrosis Factor Inhibitors/administration & dosage , Anti-Bacterial Agents/administration & dosage , Disease Progression , Doxycycline/administration & dosage , Female , HLA-B27 Antigen/genetics , Humans , Middle Aged , Rickettsia rickettsii/drug effects , Spondylarthritis/diagnosis , Spondylarthritis/genetics , Spondylarthritis/immunology , Spotted Fever Group Rickettsiosis/diagnosis , Spotted Fever Group Rickettsiosis/drug therapy , Spotted Fever Group Rickettsiosis/immunology , Treatment Outcome
15.
Emerg Infect Dis ; 24(11): 2077-2079, 2018 11.
Article En | MEDLINE | ID: mdl-30334710

We investigated 16 Japanese spotted fever cases that occurred in southeastern China during September-October 2015. Patients had fever, rash, eschar, and lymphadenopathy. We confirmed 9 diagnoses and obtained 2 isolates with high identity to Rickettsia japonica strain YH. R. japonica infection should be considered for febrile patients in China.


Anti-Bacterial Agents/therapeutic use , Rickettsia Infections/microbiology , Rickettsia/isolation & purification , Spotted Fever Group Rickettsiosis/microbiology , Ticks/microbiology , Adult , Aged , Animals , Azithromycin/therapeutic use , China , Doxycycline/therapeutic use , Female , Humans , Lymphadenopathy , Male , Middle Aged , Rickettsia/genetics , Rickettsia Infections/diagnosis , Rickettsia Infections/drug therapy , Spotted Fever Group Rickettsiosis/drug therapy , Treatment Outcome
18.
Am J Trop Med Hyg ; 98(3): 835-837, 2018 03.
Article En | MEDLINE | ID: mdl-29363442

Spotted fever group rickettsioses are transmitted by several types of arthropods (including ticks, chiggers, fleas, and lice) and are distributed worldwide. Japanese spotted fever (JSF) was discovered as an emerging rickettsiosis in 1984. The annual number of cases has increased 3-fold during the last decade. In Japan, JSF has been mainly reported in an area with warm climate that borders the Pacific Ocean. We describe a family/neighborhood cluster of three cases of JSF in an area of Japan that had previously not been considered endemic.


Arachnid Vectors/microbiology , Rickettsia/pathogenicity , Spotted Fever Group Rickettsiosis/microbiology , Ticks/microbiology , Aged , Aged, 80 and over , Animals , Anti-Bacterial Agents/therapeutic use , Female , Humans , Japan , Male , Rickettsia/drug effects , Rickettsia/physiology , Spotted Fever Group Rickettsiosis/diagnosis , Spotted Fever Group Rickettsiosis/drug therapy , Spotted Fever Group Rickettsiosis/pathology
20.
Pediatr Dermatol ; 34(4): e179-e181, 2017 Jul.
Article En | MEDLINE | ID: mdl-28544092

African tick-bite fever (ATBF), a tickborne disease endemic in rural areas of sub-Saharan Africa and the West Indies caused by Rickettsia africae, has been recognized as an emerging health problem in recent years. ATBF has been reported as the second most commonly documented etiology of fever, after malaria, in travelers who return ill from sub-Saharan Africa. Most cases reported in the literature occurred in middle-aged adults, so the incidence of ATBF in children is unclear. We report a cluster of three cases of ATBF that occurred in children ages 7 to 16 years after returning from a game-hunting safari in South Africa.


Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Spotted Fever Group Rickettsiosis/diagnosis , Adolescent , Child , Fever/etiology , Humans , Male , Rickettsia , Skin Ulcer/etiology , South Africa , Spotted Fever Group Rickettsiosis/drug therapy , Travel
...